Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

147.04USD
22 Nov 2017
Change (% chg)

$1.93 (+1.33%)
Prev Close
$145.11
Open
$145.42
Day's High
$147.37
Day's Low
$144.91
Volume
306,753
Avg. Vol
594,335
52-wk High
$167.70
52-wk Low
$71.50

Latest Key Developments (Source: Significant Developments)

Vertex reports Q3 non-GAAP earnings per share $0.53
Wednesday, 25 Oct 2017 04:01pm EDT 

Oct 25 (Reuters) - Vertex Pharmaceuticals Inc :Vertex reports third-quarter 2017 financial results.Q3 non-GAAP earnings per share $0.53.Q3 GAAP loss per share $0.41.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Vertex Pharmaceuticals Inc says ‍third-quarter 2017 cystic fibrosis product revenues of $550 million, up 34% versus Q3 2016​.Says ‍increased its total 2017 CF product revenue guidance, including ORKAMBI and KALYDECO revenue guidance​.Vertex Pharmaceuticals Inc qtrly ‍product revenues for ORKAMBI $336 million and $213 million for KALYDECO​.Says ‍reiterated its 2017 combined GAAP and non-GAAP research and development and SG&A expense guidance​.Says ‍now expects total 2017 CF product revenues of $2.10 to $2.15 billion​.Vertex Pharmaceuticals Inc ‍increases FY ORKAMBI revenue guidance to $1.29 to $1.32 billion and KALYDECO revenue guidance to $810 to $830 million​.  Full Article

FDA approves Kalydeco(Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations
Tuesday, 1 Aug 2017 08:01am EDT 

Aug 1 (Reuters) - Vertex Pharmaceuticals Inc :FDA approves Kalydeco (Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations.Says ‍guidance range for total CF product revenues in 2017 is now $1.87 billion to $2.1 billion​.Vertex Pharmaceuticals Inc- ‍vertex increased its guidance for 2017 Kalydeco product revenues to a range of $770 million to $800 million​.Says ‍increased its guidance for 2017 Kalydeco product revenues to a range of $770 million to $800 million​.  Full Article

Vertex interested in early stage assets consistent with CF focus
Wednesday, 26 Jul 2017 06:05pm EDT 

July 26 (Reuters) - Vertex Pharmaceuticals Inc :Vertex says interested in acquiring early stage assets in disease areas consistent with cystic fibrosis.Vertex says expects to pick best regimens, doses for next generation triple combination CF treatments by early 2018.Vertex Pharmaceuticals says does not anticipate ending year at low end of its forecast range.  Full Article

Vertex Q2 non-GAAP earnings per share $0.39
Wednesday, 26 Jul 2017 04:01pm EDT 

July 26 (Reuters) - Vertex Pharmaceuticals Inc ::Vertex reports second-quarter 2017 financial results.Q2 non-GAAP earnings per share $0.39.Q2 GAAP earnings per share $0.07.Vertex Pharmaceuticals Inc says reiterates 2017 guidance for Orkambi and Kalydeco product revenues.Q2 earnings per share view $0.35 -- Thomson Reuters I/B/E/S.Vertex Pharmaceuticals Inc says pipeline of investigational cf medicines continues to progress and expand to support goal of treating all people with CF.Vertex Pharmaceuticals Inc - ‍vertex expects total 2017 CF product revenues of $1.84 to $2.07 billion, comprised of orkambi and kalydeco product revenues​.Vertex Pharmaceuticals Inc - ‍continues to expect total 2017 product revenues for orkambi of $1.1 to $1.3 billion​.Qtrly net product revenues from orkambi were $324.4 million compared to $245.5 million for Q2 of 2016.Vertex Pharmaceuticals Inc - ‍continues to expect total 2017 product revenues for kalydeco of $740 to $770 million​.Qtrly net product revenues from kalydeco were $189.6 million compared to $180.2 million for Q2 of 2016.Vertex Pharmaceuticals Inc - ‍updated its total 2017 guidance for combined non-gaap research and development and SG&A expenses to a range of $1.33 to $1.36 billion​.Vertex Pharmaceuticals Inc - sees 2017 ‍updated GAAP research and development and SG&A expenses to a range of $1.79 to $1.92 billion​.  Full Article

Concert Pharmaceuticals terminates Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement
Monday, 24 Jul 2017 07:00am EDT 

July 24 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals announces termination of the Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement with Vertex.Expiration of Hart-Scott-Rodino act waiting period represents final regulatory closing condition required to complete asset purchase.Termination for pending sale of CTP-656 and other assets related to treatment of cystic fibrosis by Concert to Vertex Pharmaceuticals.  Full Article

Vertex announces reimbursement agreement for ORKAMBI in Italy
Thursday, 13 Jul 2017 04:00am EDT 

July 13 (Reuters) - Vertex Pharmaceuticals Inc ::Vertex announces reimbursement agreement in Italy for ORKAMBI(®) (Lumacaftor/Ivacaftor).  Full Article

X-Chem and Vertex enter into multi-target genetic disease collaboration
Tuesday, 16 May 2017 08:38am EDT 

May 16 (Reuters) - Vertex Pharmaceuticals Inc :X-Chem and Vertex enter into multi-target genetic disease collaboration.X-Chem - Vertex will have the option to license lead-like hits discovered under the collaboration.X-Chem - Vertex will be responsible for further development and commercialization of the resulting programs.X-Chem - will receive an upfront payment and potential research, development and regulatory milestones and licensing fees.  Full Article

Vertex Q1 non-gaap earnings per share $0.41
Thursday, 27 Apr 2017 04:01pm EDT 

April 27 (Reuters) - Vertex Pharmaceuticals Inc ::Vertex reports first-quarter 2017 financial results.Q1 non-gaap earnings per share $0.41.Q1 gaap earnings per share $0.99.Qtrly total cf product revenues were $480.6 million compared to $393.6 million for q1 of 2016.Qtrly net product revenues from orkambi were $294.9 million compared to $223.1 million for q1 of 2016.Qtrly net product revenues from kalydeco were $185.7 million, compared to $170.5 million for q1 of 2016.Reiterated its 2017 guidance for orkambi revenues and combined gaap and non-gaap research and development and sg&a expense.Increased its 2017 revenue guidance for kalydeco.Increased its total 2017 product revenue guidance for kalydeco to $710 to $730 million.  Full Article

Vertex to acquire CTP-656 from Concert Pharmaceuticals
Monday, 6 Mar 2017 07:00am EST 

Vertex Pharmaceuticals Inc : Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis . Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments . Vertex Pharmaceuticals Inc- signed a definitive asset purchase agreement to acquire CTP-656 from concert pharmaceuticals . Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating underlying cause of CF . Vertex Pharmaceuticals Inc - Vertex will pay concert $160 million in cash for all worldwide development and commercialization rights to CTP-656 .Vertex Pharmaceuticals - Concert's board of directors unanimously supports transaction and recommends that concert's shareholders vote in favor of it.  Full Article

Vertex to acquire CTP-656 from Concert Pharmaceuticals
Monday, 6 Mar 2017 07:00am EST 

Vertex Pharmaceuticals Inc :Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis.  Full Article

BRIEF-Vertex receives CHMP positive opinion for Orkambi for the treatment of children with cystic fibrosis ages 6-11

* Vertex receives CHMP positive opinion for Orkambi® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis ages 6-11 with two copies of the f508del mutation in the European Union Source text for Eikon: Further company coverage: